Dianthus Therapeutics, Inc. /DE/ (DNTH)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $2M
- Sep 17 · Routine
- Form 4 sales
- 55
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineJul 9 2026
Sold 31,249 shares at $101.03 ($3.2M)
Savitz Ryan, EVP, CFO & CBO
10b5-1 planSold 100% of holdings ($3.2M position)0 shares left1.6x usual sizeFiling
- 2 Form 4 saleRoutineAug 7 +29 days
Sold 166,000 shares at $108.11 ($17.9M)
Garcia Marino, CEO AND PRESIDENT
10b5-1 planSold 71.8% of holdings ($25M position)65,292 shares leftFiling
- 3 Form 4 saleRoutineAug 10 +3 days
Sold 2,777 shares at $109.55 ($304k)
Read Simon, Director
10b5-1 planSold 100% of holdings ($304k position)0 shares leftFirst sale on recordFiling
- 4 Form 4 saleRoutineAug 10 same day
Sold 20,000 shares at $110.44 ($2.2M)
Veness Adam M, SVP, General Counsel and Sec.
10b5-1 planSold 100% of holdings ($2.2M position)0 shares leftFiling
- 5 Form 4 saleRoutineAug 10 same day
Sold 7,750 shares at $109.01 ($845k)
McGeorge Anne, Director
10b5-1 planSold 100% of holdings ($845k position)0 shares leftFirst sale on recordFiling
- 6 Form 4 saleRoutineAug 19 +9 days
Sold 2,778 shares at $117.55 ($327k)
Read Simon, Director
10b5-1 planSold 100% of holdings ($327k position)0 shares leftFiling
- 7 Form 4 saleRoutineSep 1 +13 days
Sold 23,124 shares at $106.41 ($2.5M)
Randhawa Simrat, EVP, Head of R&D
10b5-1 planSold 85.3% of holdings ($2.9M position)4,000 shares left0.7x usual sizeFiling
- 8 Form 4 saleRoutineSep 17 +16 days
Sold 20,000 shares at $101.38 ($2M)
Carr Edward, CHIEF ACCOUNTING OFFICER
10b5-1 planSold 100% of holdings ($2M position)0 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (55)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Carr Edward | CHIEF ACCOUNTING OFFICER | Form 4 sale | 20,000 | $2M | 100.0% | Routine | SEC |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Form 4 sale | 23,124 | $2.5M | 85.3% | Routine | SEC |
| Aug 19, 2026 | Read Simon | Director | Form 4 sale | 2,778 | $327k | 100.0% | Routine | SEC |
| Aug 10, 2026 | McGeorge Anne | Director | Form 4 sale | 7,750 | $845k | 100.0% | Routine | SEC |
| Aug 10, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Form 4 sale | 20,000 | $2.2M | 100.0% | Routine | SEC |
| Aug 10, 2026 | Read Simon | Director | Form 4 sale | 2,777 | $304k | 100.0% | Routine | SEC |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Form 4 sale | 166,000 | $17.9M | 71.8% | Routine | SEC |
| Jul 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Form 4 sale | 31,249 | $3.2M | 100.0% | Routine | SEC |
| Jun 17, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Form 4 sale | 30,000 | $2.4M | 100.0% | Routine | SEC |
| Jun 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Form 4 sale | 26,530 | $2.4M | 86.9% | Routine | SEC |
| May 8, 2026 | Soteropoulos Paula | Director | Form 4 sale | 599 | $51k | 100.0% | Routine | SEC |
| Apr 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Form 4 sale | 8,224 | $739k | 100.0% | Routine | SEC |
| Mar 31, 2026 | Savitz Ryan | EVP, CFO & CBO | Form 4 sale | 114,367 | $9.5M | 100.0% | Routine | SEC |
| Mar 31, 2026 | Soteropoulos Paula | Director | Form 4 sale | 599 | $48k | 100.0% | Routine | SEC |
| Mar 24, 2026 | Soteropoulos Paula | Director | Form 4 sale | 27,594 | $2.2M | 100.0% | Routine | SEC |
| Mar 12, 2026 | Randhawa Simrat | EVP, Head of R&D | Form 4 sale | 33,830 | $2.8M | 100.0% | Routine | SEC |
| Mar 12, 2026 | Garcia Marino | CEO AND PRESIDENT | Form 4 sale | 122,918 | $10M | 100.0% | Routine | SEC |
| Mar 12, 2026 | Carr Edward | CHIEF ACCOUNTING OFFICER | Form 4 sale | 43,682 | $3.6M | 100.0% | Routine | SEC |
| Dec 4, 2025 | Savitz Ryan | CFO & CBO | Form 4 sale | 20,000 | $904k | 100.0% | Routine | SEC |
| Nov 14, 2025 | Randhawa Simrat | EVP, Head of R&D | Form 4 sale | 196,538 | $7.4M | 98.0% | Routine | SEC |
| Sep 9, 2025 | Savitz Ryan | CFO & CBO | Form 4 sale | 20,000 | $700k | 100.0% | Routine | SEC |
| Feb 8, 2023 | Trv Gp IV, LLC | 10% owner | Form 4 sale | 3.7M | $3.1M | 54.7% | Unusual | SEC |
| Sep 16, 2021 | Stants Kristen | Chief People Officer | Form 4 sale | 5,736 | $39k | 28.7% | Unusual | SEC |
| Sep 16, 2021 | Mahoney Stephen F. | Officer | Form 4 sale | 5,736 | $39k | 28.7% | Unusual | SEC |
| Sep 16, 2021 | Deardorf Caren | Chief Commercial Officer | Form 4 sale | 6,238 | $42k | 31.2% | Unusual | SEC |
| Sep 16, 2021 | Gardner Jason | Officer | Form 4 sale | 14,340 | $97k | 4.8% | Unusual | SEC |
| Sep 16, 2021 | Beetham Thomas W. | Officer | Form 4 sale | 6,103 | $41k | 30.5% | Unusual | SEC |
| Sep 16, 2021 | Olson Lisa | Officer | Form 4 sale | 5,736 | $39k | 28.7% | Unusual | SEC |
| Sep 16, 2021 | Nichols David Wayne | Chief Technical Officer | Form 4 sale | 5,694 | $38k | 28.5% | Unusual | SEC |
| Jan 10, 2020 | Gardner Jason | Officer, Director | Form 4 sale | 11,200 | $171k | 4.3% | Plan not stated | SEC |
| Jan 2, 2020 | Davis John C. Jr | Chief Medical Officer | Form 4 sale | 11,294 | $170k | 57.6% | Unusual | SEC |
| Jan 2, 2020 | Gardner Jason | Officer, Director | Form 4 sale | 2,800 | $42k | 1.1% | Plan not stated | SEC |
| Dec 24, 2019 | Isacson Christina K. | Chief Business Officer | Form 4 sale | 4,463 | $71k | 5.1% | Plan not stated | SEC |
| Dec 24, 2019 | Zdraveski Zoran | Officer | Form 4 sale | 7,902 | $126k | 5.8% | Plan not stated | SEC |
| Dec 23, 2019 | Zdraveski Zoran | Officer | Form 4 sale | 4,181 | $67k | 3.0% | Plan not stated | SEC |
| Dec 23, 2019 | Isacson Christina K. | Chief Business Officer | Form 4 sale | 9,867 | $158k | 10.1% | Plan not stated | SEC |
| Dec 23, 2019 | Gardner Jason | Officer, Director | Form 4 sale | 2,897 | $44k | 1.1% | Plan not stated | SEC |
| Dec 20, 2019 | Gardner Jason | Officer, Director | Form 4 sale | 76,711 | $1.2M | 22.2% | Plan not stated | SEC |
| Dec 20, 2019 | Davis John C. Jr | Chief Medical Officer | Form 4 sale | 919 | $14k | 10.0% | Plan not stated | SEC |
| Dec 10, 2019 | Gardner Jason | Officer, Director | Form 4 sale | 4,392 | $66k | 1.3% | Plan not stated | SEC |
| Dec 10, 2019 | Davis John C. Jr | Chief Medical Officer | Form 4 sale | 21,669 | $325k | 72.3% | Unusual | SEC |
| Dec 2, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 7,500 | $98k | 3.0% | Plan not stated | SEC |
| Nov 20, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 5,000 | $60k | 2.0% | Plan not stated | SEC |
| Nov 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 5,000 | $53k | 1.9% | Plan not stated | SEC |
| Oct 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 5,000 | $50k | 1.9% | Plan not stated | SEC |
| Sep 19, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 1,656 | $20k | 0.6% | Plan not stated | SEC |
| Sep 12, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 844 | $10k | 0.3% | Plan not stated | SEC |
| Sep 3, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 5,000 | $51k | 1.8% | Plan not stated | SEC |
| Aug 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 7,500 | $101k | 2.7% | Plan not stated | SEC |
| Jul 1, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 7,500 | $108k | 2.6% | Plan not stated | SEC |
| Jun 21, 2019 | Isacson Christina K. | Chief Business Officer | Form 4 sale | 5,415 | $87k | 5.2% | Plan not stated | SEC |
| Jun 21, 2019 | Gardner Jason | Officer, Director | Form 4 sale | 14,000 | $212k | 3.9% | Plan not stated | SEC |
| Jun 17, 2019 | Cooke Michael P. | Chief Scientific Officer | Form 4 sale | 7,500 | $104k | 2.6% | Plan not stated | SEC |
| Mar 20, 2019 | Atlas Venture Associates X, LLC | 10% owner | Form 4 sale | 14,245 | $254k | 100.0% | Unusual | SEC |
| Mar 20, 2019 | Booth Bruce | Director | Form 4 sale | 14,245 | $254k | 100.0% | Unusual | SEC |